Although its physiological relevance remains to be elucidated, GPR37 may be an attractive target for PD, since it interacts with the D2R, the 5-HT4R and also with the adenosine A2A receptor, A2AR. In PD, GPR37 acts as an A2AR inhibitor via receptor oligomerization. This evidence concerns the gene HTR4 and Parkinson disease.